Mergers and Acquisitions in the Pharmaceutical and Biotech Industries

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Managerial and Decision Economics

• Publication date

  2007-06-01

• Fields of study

  Medicine, Business, Economics

• Identifiers
  DOI 10.2139/ssrn.468301
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The outsourcing of R&D through acquisitions in the pharmaceutical industry

  2006influential reference
• Pharmaceutical Industry Profile

  2005cited by this paper
• Examining the link between price regulation and pharmaceutical R&D investment.

  2005cited by this paper
• Biotech-Pharmaceutical Alliances as a Signal of Asset and Firm Quality

  2005influential reference
• Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group

  2005cited by this paper
• Do Shareholders of Acquiring Firms Gain from Acquisitions?

  2003cited by this paper
• Hospital consolidation and costs: another look at the evidence.

  2003cited by this paper
• Does Investor Misvaluation Drive the Takeover Market

  2003cited by this paper
• Efficient estimation of average treatment effects using the estimated propensity score

  2003cited by this paper
• The impact of mergers and acquisitions on company employment in the United Kingdom

  2002cited by this paper
• New Evidence and Perspectives on Mergers

  2001cited by this paper
• EVIDENCE ON MERGERS AND ACQUISITIONS

  2001cited by this paper
• Corporate Governance and Merger Activity in the United States: Making Sense of the 1980s and 1990s

  2001influential reference
• Explaining the Diversification Discount

  2001cited by this paper
• Paths to Creating Value in Pharmaceutical Mergers

  2000cited by this paper
• Managerial Decisions and Long-Term Stock Price Performance

  2000cited by this paper
• Does Diversification Cause the "Diversification Discount"?

  2000cited by this paper
• Consolidation in the Medical Care Marketplace

  2000cited by this paper
• Agency Costs of Free Cash Flow, Corporate Finance, and Takeovers

  1999cited by this paper
• Investigating the economic role of mergers

  1998cited by this paper
• The impact of industry shocks on takeover and restructuring activity

  1996cited by this paper
• The Modern Industrial Revolution, Exit, and the Failure of Internal Control Systems

  1993cited by this paper
• The Voluntary Restructuring of Large Firms in Response to Performance Decline

  1992cited by this paper
• The Effect of Takeover Activity on Corporate Research and Development

  1987cited by this paper
• The central role of the propensity score in observational studies for causal effects

  1983cited by this paper
• The effectiveness of adjustment by subclassification in removing bias in observational studies.

  1968cited by this paper
• Labor as a Quasi-Fixed Factor

  1962cited by this paper

• Mergers and Investments: Where Do We Stand?

  2026cites this paper
• A case study assessing the impact of M&A and licensing on FDA drug approvals of leading pharmaceutical companies.

  2025cites this paper
• Acquiring Growth: How Innovative Firms Leverage M&As for Competitive Advantage

  2025cites this paper
• Upfront payments to venture‐backed startups in technology alliances: Bargaining effects of VC affiliations

  2025cites this paper
• Bargaining Power Neutrality in Mergers and Acquisitions

  2025cites this paper
• Acquisitions as catalysts for inventor departures in the biotechnology industry

  2025influential citation
• Model Evaluation of Post-M&A Success Metrics in the German Biopharmaceutical Industry

  2025cites this paper
• The impact of biotech acquisitions on inventor productivity

  2025cites this paper
• How does news affect biopharma stock prices?: An event study

  2024cites this paper
• Seeking Efficiency or Price Gouging? Evidence from Pharmaceutical Mergers

  2024cites this paper
• Impact of Mergers and Acquisitions on Corporate Stakeholder Practices in Nepalese Commercial Banks

  2024cites this paper
• The pharmaceutical productivity gap - incremental decline in R&D efficiency despite transient improvements.

  2024cites this paper
• Do Acquisitions Enrich Corporate Knowledge and Organizational Capital?

  2024cites this paper
• Pharmaceutical multinational corporations (MNCs) and their exit from low and middle income countries (LMICs): analysing the causes and consequences

  2024cites this paper
• The heterogeneous impacts of M&As on renewable energy firms’ innovation: Comparative analysis of China, the US and EU

  2023cites this paper
• Mergers, Prices, and Innovation: Lessons from the Pharmaceutical Industry

  2023cites this paper
• The Effect of Mergers and Acquisitions on Efficiency: Evidence from the Pharmaceutical Industry

  2023influential citation
• The impact of mergers and acquisitions on shareholders' value: an empirical study of pharmaceutical companies

  2023cites this paper
• The Effects Of Mergers and Acquisitions Transactions

  2023cites this paper
• Evaluating merger effects

  2023cites this paper
• What Motivates Mergers and Acquisitions in India?

  2023cites this paper
• The economic geographies of mergers and acquisitions (M&As)

  2023cites this paper
• Interstate migration‐based social networks and M&A decisions

  2023cites this paper
• How Does Tobin’s Q Respond to Merger and Acquisition Announcements: Evidence of Listed Indian Firms

  2023cites this paper
• The impact of mergers and acquisitions on performance of firms: A pre- and post-TRIPS analysis of India's pharmaceutical industry

  2023cites this paper
• XYZ Biotech: A Fictional Business Development Case Utilizing Quantitative Tools to Evaluate a New Antibody-Drug-Conjugate Opportunity for Metastatic Breast Cancer

  2023cites this paper
• A Study on Impact of Merger and Acquisition on Financial Performance of Agri-Food Companies

  2022cites this paper
• Pharmaceutical spending and early-stage innovation in EU countries

  2022cites this paper
• Financing Biomedical Innovation

  2022cites this paper
• The Impact of Acquisitions in the Biotechnology Sector on R&D Productivity

  2022cites this paper
• D’une pandémie à l’autre, rareté artificielle et rente sous brevet de médicament

  2022cites this paper
• Quantum jump in biopharmaceutical industry: a case of Korea’s catching up with Europe and US

  2022cites this paper
• Patents over patients? Exploring the variegated financialization of the pharmaceuticals industry through mergers and acquisitions

  2022influential citation
• Competition and Innovation: The Breakup of IG Farben

  2022cites this paper
• Are Blockchain and Cryptocurrency M&As Harder to Close?

  2022cites this paper
• Linking ownership acquired in Chinese firms to post-acquisition innovation performance: role of institutional distance

  2021cites this paper
• Stock Payment, State Ownership and Innovation Performance in China’s Pharmaceutical M&As

  2021cites this paper
• Mergers and innovation: Evidence from the hard disk drive market

  2021cites this paper
• When capital markets discount R&D expenditures: the problemistic search effect

  2021cites this paper
• UNDERSTANDING DETERMINANTS OF DOMESTIC MERGERS AND ACQUISITIONS THROUGH LITERATURE REVIEW

  2021cites this paper
• Cross-border mergers and acquisitions for innovation

  2021cites this paper
• The Impact of Mergers and Acquisitions and Sustainability on Company Performance in the Pharmaceutical Sector

  2021cites this paper
• The role of patent expiration in acquisition decision and target selection in the pharmaceutical industry

  2021influential citation
• Innovation crisis in the pharmaceutical industry? A survey

  2021cites this paper
• How Do Pharmaceutical Companies Overcome a Corporate Productivity Crisis? Business Diversification into Medical Devices for Growth Potential

  2021cites this paper
• Are M&As an opportunity for HR to join the top table? The case of Sanofi’s emerging international strategy

  2021cites this paper
• Biomed Europa: After the coronavirus, a public infrastructure to overcome the pharmaceutical oligopoly

  2021cites this paper
• The Impact of Research and Development (R&D) Intensity on Financial Performance and Firm Value: An Empirical Study on Pharmaceutical Companies Listed on Egyptian Stock Exchange

  2020cites this paper
• Collaborative partnerships in the automotive industry: key motives and resource integration strategy

  2020cites this paper
• Dynamic Mergers Effects on R&D Investments and Drug Development Across Research Phases in the Pharmaceutical Industry

  2020cites this paper
• Moderating Effect of the Continental Factor on the Business Strategy and M&A Performance in the Pharmaceutical Industry for Sustainable International Business

  2020cites this paper
• M&As in Germany: measuring success for the pharma and biotech industries

  2020cites this paper
• Innovation spillover and merger decisions

  2020cites this paper
• Overview of the causes and management of drug shortages in the United States and in Hungary

  2020cites this paper
• Pharmaceutical industry’s changing market dynamics

  2020cites this paper
• Firm-Level Determinants of Foreign Investment and M&A Activity

  2020cites this paper
• Penciptaan Nilai Perusahaan: Spesial Isu Merger dan Akuisisi Perusahaan Publik di Indonesia

  2020cites this paper
• A STUDY ON MERGER AND ACQUISITION OF SELECTED COMPANIES OF COSMETIC INDUSTRY

  2020cites this paper
• Rushed Innovation: Evidence from Drug Licensing

  2020cites this paper
• The Best or Worst Deal in the History of Deals: Determinants of Healthcare M&A Outcomes

  2020influential citation
• ERASMUS UNIVERSITY ROTTERDAM The role of research & development within pharmaceutical mergers & acquisitions in OECD countries

  2020influential citation
• MOLECULAR DOCKING SOFTWARE’S APPLICATIONS AND BASIC CHALLENGES FACED: A REVIEW

  2020cites this paper
• Impact of corporate governance, financial and regulatory factors on firms’ acquisition ability

  2020cites this paper
• Davids versus Goliaths: Epigenetic dynamics and structural change in the Swedish innovation system

  2020cites this paper
• Decision-support challenges in the chemical-pharmaceutical industry: Findings and future research directions

  2020cites this paper
• Econometric Assessment of the Impact of the Buyer Company’s Financial Position on the M&A Effectiveness (in the Pharmaceutical Industry)

  2020cites this paper
• Determinants of Short-Term Value Creation through M&A for the Acquirer -The event study of the pharmaceutical industry focus on the Western European market

  2019influential citation
• Shareholder wealth-effects on corporate acquisitions : evidence from pharmaceutical industry

  2019influential citation
• The factors affecting technology transaction value in Vietnam: technology demand approach

  2019cites this paper
• The Influence of a Firm’s Capability and Dyadic Relationship of the Knowledge Base on Ambidextrous Innovation in Biopharmaceutical M&As

  2019cites this paper
• Does Technology Matter When Selecting a Target Firm in an M&A? Some Evidence on a European M&A Sample

  2019cites this paper
• The effect of acquired company EBITDA on the deal value within M&A context

  2019influential citation
• Start-ups as Buyers in Technology Markets: Evidence from the Bio-pharmaceutical Industry

  2019influential citation
• Resurrecting the Size Effect: Firm Size, Profitability Shocks, and Expected Stock Returns

  2019cites this paper
• Rushed Innovation: Reactive Licensing in the Pharmaceutical Industry

  2019cites this paper
• Are explicit knowledge transfers clustered or diffused in the U.S. biopharmaceutical market sector?

  2019cites this paper
• Collaboration, Innovation, and Funding as Survival Factors for Canadian Biotechnology SMEs

  2019cites this paper
• One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry.

  2019cites this paper
• Partnership and innovation in the pharmaceutical industry: the case of clinical research

  2019cites this paper
• Do mergers and acquisitions improve firms' financial performance? The case of the U.S. generic drug industry

  2019cites this paper
• Intangibles and the Market Value of Biopharmaceutical Startups

  2018cites this paper
• Find and Replace: R&D Investment Following the Erosion of Existing Products

  2018cites this paper
• GlaxoSmithKline Merger

  2018cites this paper
• Bibliography

  2018cites this paper
• Intellectual Property for Pharmaceuticals and Plant Genetic Resources in Historical Perspective

  2018cites this paper
• Corporate venture capital as a real option in the markets for technology

  2018cites this paper
• R&D Success in Pharmaceutical Markets: A Duration Model Approach

  2018cites this paper
• Determinants of Vertical Integration: Investment Efficiency, Product Differentiation and Firm Size

  2018cites this paper
• Essays on M&AS and Innovation

  2018influential citation
• Financialized Corporations in a National Innovation System: The U.S. Pharmaceutical Industry

  2018influential citation
• The impact of regulatory changes and mergers on electricity prices, electricity workers' wages, and research and development

  2018cites this paper
• The role of capital capacity, spatial competition, and strategic orientation to mergers and acquisitions by U.S. farmer cooperatives

  2018cites this paper
• Returns on different types of investment in the global pharmaceutical industry

  2018cites this paper
• Informed Trading around Biotech M&As

  2018cites this paper
• Reactive Outsourcing of Technological Innovations

  2018cites this paper
• Mergers and innovation: evidence from a panel of US firms*

  2018influential citation
• When do investors reward acquisitions and divestitures? The contrasting implications of normative and behavioral economic theories

  2018cites this paper
• Market Value, Market Share, and Mergers: Evidence from a Panel of U.S. Firms

  2018cites this paper
• Is innovation a factor in merger decisions? Evidence from a panel of US firms

  2018influential citation
• Resurrecting the Size Effect: Firm Size, Profitability Shocks, and Expected Stock Returns

  2018cites this paper